Concepedia

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Amit M. Oza, Anna V. Tinker, Ana Oaknin, Ronnie Shapira‐Frommer, Iain A. McNeish, Elizabeth M. Swisher, Isabelle Ray‐Coquard, Katherine M. Bell‐McGuinn, Robert L. Coleman, David M. O’Malley,

Gynecologic Oncology · 2017 · 272 citations · 21 references

DOIFull text

Open access

Abstract

Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile.

References

21

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.5K citations

, , +7

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation

Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al. · Journal of Clinical Oncology · 2014 · 1.7K citations · Full text

Brca1 Controls Homology-Directed DNA Repair

Mary Ellen Moynahan, Joanne W Chiu, Beverly H. Koller et al. · Molecular Cell · 1999 · 1.2K citations · Full text